

# Alberto Zambelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3053338/publications.pdf>

Version: 2024-02-01

52  
papers

2,571  
citations

257357

24  
h-index

197736

49  
g-index

55  
all docs

55  
docs citations

55  
times ranked

5231  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e27349.	2.1	2
2	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
3	Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic. <i>Oncologist</i> , 2021, 26, 341-347.	1.9	7
4	International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. <i>JAMA Network Open</i> , 2021, 4, e2112596.	2.8	33
5	Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19. <i>Scientific Reports</i> , 2021, 11, 20238.	1.6	10
6	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
7	Targeting the intrinsically disordered architectural High Mobility Group A (HMGA) oncoproteins in breast cancer: learning from the past to design future strategies. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 953-969.	1.5	7
8	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151
9	Can multigene assays widen their clinical usefulness in early breast cancer treatment choice during the current COVID-19 outbreak in Italy?. <i>ESMO Open</i> , 2020, 5, e000836.	2.0	2
10	International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. <i>Npj Digital Medicine</i> , 2020, 3, 109.	5.7	128
11	Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study. <i>Breast</i> , 2020, 52, 1-7.	0.9	8
12	Optimisation and validation of a remote monitoring system (Onco-TreC) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study. <i>BMJ Open</i> , 2017, 7, e014617.	0.8	25
13	Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 121.	1.8	18
14	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. <i>PLoS ONE</i> , 2016, 11, e0156221.	1.1	2
15	A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0162407.	1.1	74
16	Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. <i>Nature Cell Biology</i> , 2016, 18, 897-909.	4.6	205
17	Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 109-123.	2.5	41
18	Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival. <i>European Journal of Cancer</i> , 2016, 52, 41-49.	1.3	33

#	ARTICLE	IF	CITATIONS
19	Trabectedin for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2016, 25, 105-115.	1.9	31
20	Cellular and molecular determinants of all-cause mortality in breast cancer: Luminal phenotype and RAR expression. EMBO Molecular Medicine, 2015, 7, 950-972.	3.3	60
21	A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression. BMC Cancer, 2015, 15, 397.	1.1	6
22	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute Monographs, 2015, 2015, 1-3.	0.9	0
23	Effectiveness of Trastuzumab in First-Line HER2+ Metastatic Breast Cancer After Failure in Adjuvant Setting: A Controlled Cohort Study. Oncologist, 2014, 19, 1209-1215.	1.9	25
24	Prolyl isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Molecular Medicine, 2014, 6, 99-119.	3.3	130
25	Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice. Breast, 2014, 23, 573-578.	0.9	19
26	Retinoids and breast cancer: From basic studies to the clinic and back again. Cancer Treatment Reviews, 2014, 40, 739-749.	3.4	113
27	Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treatment Reviews, 2013, 39, 541-550.	3.4	106
28	Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. European Journal of Cancer, 2013, 49, 520-530.	1.3	141
29	Analysis of SEMA6B gene expression in breast cancer: Identification of a new isoform. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 4543-4553.	1.1	16
30	Short commentaries on data published by Petit et al. on locoregional risk after lipofilling in breast cancer patients. Breast, 2013, 22, 96-97.	0.9	3
31	Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study. Oncologist, 2013, 18, 795-801.	1.9	43
32	Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy. Experimental and Therapeutic Medicine, 2013, 5, 902-906.	0.8	16
33	An ICT infrastructure to integrate clinical and molecular data in oncology research. BMC Bioinformatics, 2012, 13, S5.	1.2	26
34	No correlation between plasma D-dimer levels and lymph node involvement in operable breast cancer. Breast, 2012, 21, 220.	0.9	13
35	ONCO-i2b2: Improve Patients Selection through Case-Based Information Retrieval Techniques. Lecture Notes in Computer Science, 2012, , 93-99.	1.0	2
36	Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast, 2011, 20, 176-183.	0.9	42

#	ARTICLE	IF	CITATIONS
37	Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 399-411.	1.1	35
38	Absence of the K303R estrogen receptor $\hat{\pm}$ mutation in breast cancer patients exhibiting different responses to aromatase inhibitor anastrozole neoadjuvant treatment. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 939-942.	0.8	5
39	From cancer patients to cancer survivors: The issue of Cardioncology $\hat{\pm}$ A biological perspective. <i>European Journal of Cancer</i> , 2010, 46, 697-702.	1.3	8
40	Seizure associated with palonosetron. <i>Supportive Care in Cancer</i> , 2009, 17, 217-217.	1.0	9
41	Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. <i>Lung Cancer</i> , 2008, 60, 455-457.	0.9	48
42	A Randomized Multicenter Study of Optimal Circadian Time of Vinorelbine Combined with Chronomodulated 5 $\hat{\pm}$ Fluorouracil in Pretreated Metastatic Breast Cancer Patients: EORTC Trial 05971. <i>Chronobiology International</i> , 2008, 25, 680-696.	0.9	25
43	Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma. <i>BMC Cancer</i> , 2005, 5, 109.	1.1	10
44	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. <i>Cancer</i> , 2005, 104, 2099-2103.	2.0	50
45	Incidence of Human Cytomegalovirus Infection in Patients with Refractory Solid Tumors Receiving Nonmyeloablative Allogeneic Stem Cell Transplants versus Recipients of Standard SCT for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 423-428.	2.0	5
46	Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2. <i>Clinical Cancer Research</i> , 2004, 10, 5650-5655.	3.2	470
47	Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 31-38.	1.3	8
48	Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen. <i>Cancer</i> , 2002, 94, 2409-2415.	2.0	120
49	T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8 $\hat{\pm}$ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. <i>Immunology</i> , 2002, 106, 27-37.	2.0	51
50	Circulating CD33 $\hat{\pm}$ large mononuclear cells contain three distinct populations with phenotype of putative antigen-presenting cells including myeloid dendritic cells and CD14 $\hat{\pm}$ monocytes with their CD16 $\hat{\pm}$ subset. <i>Cytometry</i> , 2001, 45, 124-132.	1.8	20
51	Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 61, 241-247.	1.1	17
52	Relationship between size and thiazole orange fluorescence of platelets in patients undergoing high-dose chemotherapy. <i>British Journal of Haematology</i> , 1999, 106, 202-207.	1.2	49